[EN] PHOSPHONATES AND PARATHYROID HORMONE FOR OSTEOPOROSIS<br/>[FR] PHOSPHONATES ET PARATHORMONE CONTRE L'OSTEOPOROSE
申请人:THE PROCTER & GAMBLE COMPANY
公开号:WO1996007418A1
公开(公告)日:1996-03-14
(EN) The present invention provides methods of treating a human or other animal subject having a bone metabolism disorder, comprising the steps of: (a) administering to said subject a safe and effective amount of an antiresorptive compound, during a period of from about 2 weeks to about 6 months; (b) administering to said subject a safe and effective amount of a parathyroid hormone, during a period of from about 3 to about 12 months. Preferred antiresorptive compounds include bisphosphonates, estrogen compounds, and antiestrogen compounds.(FR) L'invention concerne des procédés de traitement d'un sujet humain ou animal présentant des troubles de l'ostéométabolisme, comprenant les étapes consistant (a) à administrer audit sujet une dose sans danger et efficace d'un composé antirésorption pendant une durée comprise entre environ deux semaines et environ six mois, (b) à administrer audit sujet une dose sans danger et efficace d'une parathormone pendant une durée comprise entre environ trois et environ douze mois. On peut citer parmi les composés antirésorption préférés des bisphosphonates, des composés ÷strogènes et des composés anti-÷strogènes.
[EN] METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE<br/>[FR] PROCEDES DE TRAITEMENT DE L'OSTEOPOROSE UTILISANT DES PHOSPHONATES OSTEOACTIFS ET UNE HORMONE PARATHIROÏDIENNE
申请人:THE PROCTER & GAMBLE COMPANY
公开号:WO1996007417A1
公开(公告)日:1996-03-14
(EN) The present invention provides methods of treating a human or other animal subject having a bone metabolism disorder, comprising the steps of: (a) administering to said subject a safe and effective amount of a bone active phosphonate during a period of at least about 6 months; (b) administering to said subject a safe and effective amount of a parathyroid hormone, during a period of from about 3 to about 12 months.(FR) L'invention concerne des procédés de traitement d'un sujet humain ou d'un sujet animal présentant un dérèglement du métabolisme osseux, comprenant les étapes consistant: (a) à administrer audit sujet une dose efficace et sans danger d'un phosphonate ostéoactif pendant une durée d'au moins environ 6 mois, (b) à administrer audit sujet une dose efficace et sans danger d'une hormone parathyroïdienne, pendant une durée comprise entre environ 3 et environ 12 mois.
Certain cycloalkane-1,1-diphosphonic acids and derivatives thereof
申请人:The Procter & Gamble Company
公开号:US04939131A1
公开(公告)日:1990-07-03
Novel cyclic geminal-diphosphonic acid compounds, and pharmaceutical compositions containing these compounds, which are useful for treating diseases characterized by abnormal calcium and phosphate metabolism; and a method of treating diseases characterized by abnormal calcium and phosphate metabolism utilizing these novel cyclic diphosphonic acid compounds.
Certain hexahydroindan-2,2-diphosphonic acids useful in treating
申请人:The Procter & Gamble Company
公开号:US04687768A1
公开(公告)日:1987-08-18
Novel cyclic geminal-diphosphonic acid compounds, and pharmaceutical compositions containing these compounds, which are useful for treating diseases characterized by abnormal calcium and phosphate metabolism; and a method of treating diseases characterized by abnormal calcium and phosphate metabolism utilizing these noval cyclic diphosphonic acid compounds.
Certain bicycloalkane and azabicycloalkane-1,1-diphosphonic acid
申请人:The Procter & Gamble Company
公开号:US05104863A1
公开(公告)日:1992-04-14
This invention relates to pyrindine-diphosphonic acid derivatives which are useful in treating or preventing diseases characterized by abnormal calcium and phosphate matabolism, in particular those which are characterized by abnormal bone metabolism. This invention further relates to pharmaceutical compositions which contain the novel compounds of the present invention, and to a method of treating or preventing diseases characterized by abnormal calcium and phosphate metabolism utilizing a compound of the present invention.